CLINICAL LABORATORY, cilt.67, sa.3, ss.804-820, 2021 (SCI-Expanded)
Background: Non-alcoholic steatohepatitis (NASH) has risen in prevalence substantially through the years. Although course and progression of the disease are variable, fibrosis is the most important factor. We intended to explore utility of serum biglycan (BGN) in NASH and its capacity in anticipating liver fibrosis.